Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) — The Platform Finally Paid Off, and the Market Stopped Paying Up

Independent equity research — for general information only Report date: 2026-06-21 Framing: Fundamental, competitive-advantage-driven, evidence-based. No price target and no buy/sell recommendation appears anywhere in the main analysis below. The single, deliberately-labeled exception is the Claude’s Take block immediately below, which is the author’s own independent opinion.

⚡ Claude’s Take

This block is the author’s own subjective, independent opinion. It is general information only and not investment advice. The main analysis below carries no recommendation and no price target.

Verdict: HOLD bordering on ACCUMULATE-ON-WEAKNESS. Constructive. The 20-year science experiment finally produced a profitable, fast-growing franchise — and the stock has fallen 43% from its October-2025 high right as the fundamentals inflected. You are being offered a genuine RNAi platform at its cheapest-ever sales multiple, with the entire pipeline beyond TTR thrown in close to free. The reasons it is not a table-pounding BUY are real: ~70%+ of revenue is a single protein target (TTR) into a market that is getting more competitive, the maiden GAAP profit is thinner than it looks once you charge stock comp as the real cost it is, and the IRA orphan-exemption clock is a structural overhang. Med conviction.

Entry zone I’d build in: high-$200s to low-$300s (the stock is ~$278 now, near its 52-week low). I’d accumulate more aggressively sub-$250 and treat a washout toward ~$210–230 as a gift, not a warning. Directional fair-value zone: ~$330–$430 (roughly 9–12x forward EV/product-sales and ~25–32x FY27E EPS as operating leverage compounds) — i.e., the de-rate has removed the froth without yet pricing the franchise as the durable cash machine it is becoming. Bull case $450+; downside floor cushioned by a real takeover bid (Regeneron, Roche, Novartis and Sanofi all already carry economic exposure) and by 46% incremental operating margins that make every incremental TTR dollar drop hard to the bottom line. Not a short — shorting an operating-leverage inflection with a strategic-bid floor is how careers end.

The framing is fallen-angel / de-rated quality compounder, NOT a momentum trade. The factor tape confirms it: ALNY trades below all major moving averages, is down ~29% over six months, carries a market beta of only ~0.80, and its returns are ~75% idiosyncratic — this is a stock the market has abandoned, not chased. That is the opposite of most of what’s expensive today. What flips me decisively bullish: AMVUTTRA hits the back-half ramp implied by the reiterated $4.4–4.7B TTR guide, confirming the launch isn’t stalling. What flips me bearish: BridgeBio’s acoramidis (Attruby) keeps compounding first-line share and the ATTR-CM market proves to be a price-competitive cardiology slugfest rather than a durable orphan annuity — at which point the “platform” has to start carrying the story, and that’s a 2028–2030 question, not a 2026 one.

Tag: “They cured the burn rate; the market is selling the cure.”

📈 Stock Price Action — Five-Year Event Map

Over the trailing five years ALNY round-tripped from a ~$120 low (May 2022) to an all-time closing high of $491.22 (20-Oct-2025) and has since fallen ~43% to $278.09 (18-Jun-2026) — which is also the 52-week low. The stock sits below its 21-, 50- and 200-day EMAs ($292 / $301 / $337), so the recent tape is a clean downtrend layered on top of a multi-year structural up-move. The decline is almost entirely a post-peak de-rating, not a fundamental collapse: revenue accelerated and the company turned profitable across the very window the multiple compressed. (Price levels: FACT, five-year price history. Attributed drivers: INTERPRETATION, cross-referenced to earnings prints, 8-Ks and the news feed.)

Cycle narrative. (1) ALNY entered the window as a classic pre-profit biotech, sold off with the 2022 rate shock to a $120 low. (2) The vutrisiran ATTR-PN approval and the positive APOLLO-B cardiomyopathy topline in 2022 nearly doubled the stock by setting up the much larger CM opportunity. (3) 2023 was a holding pattern awaiting the pivotal HELIOS-B CM outcomes trial. (4) HELIOS-B’s positive June-2024 topline — a mortality and cardiovascular-event benefit — was the scientific de-risking event that mattered most. (5) The March-2025 FDA approval in ATTR-CM and the subsequent blistering launch (revenue +65% for the year, first GAAP profit) carried the stock to a $491 all-time high by October 2025. (6) From there the multiple, which had run to a stretched level, compressed; the Q4-2025 print on 12-Feb-2026 candidly flagged first-quarter gross-to-net and reauthorization headwinds and the stock broke to ~$308. (7) It has since drifted to a 52-week low at $278 on competitive headlines (BridgeBio’s Attruby taking first-line share, the pending eplontersen CARDIO-TTRansform combination readout) and the persistent IRA pricing overhang — even as Q1-2026 delivered the first-ever $1B+ product-revenue quarter and a third straight profitable quarter. The price and the fundamentals have been moving in opposite directions for eight months.

1. Executive Summary

Alnylam is the world’s leading RNA-interference (RNAi) therapeutics company and, as of FY2025, a newly and structurally profitable one. After roughly two decades and a cumulative ~$6.7B accumulated deficit spent translating a Nobel-Prize-winning biology (RNAi) into approved medicines, the company crossed into GAAP profitability in 2025: revenue of $3,713.9M (+65% YoY), first-ever full-year GAAP operating income of $501.6M (13.5% margin), net income of $313.7M, and operating cash flow of $524M [FACT, ROIC/10-K]. The engine of the inflection is a single franchise — transthyretin (TTR) amyloidosis — and within it, a single drug: AMVUTTRA (vutrisiran), a quarterly subcutaneous gene silencer whose March-2025 FDA approval in ATTR cardiomyopathy (ATTR-CM) expanded its addressable population from tens of thousands of polyneuropathy patients to a heart-failure market estimated at ~200,000 patients in the US alone, >80% still untreated. AMVUTTRA generated ~$2.31B in FY2025 (+138%) and the TTR franchise (AMVUTTRA + ONPATTRO) crossed $910M in Q1-2026 alone (+153% YoY). FY2026 product-revenue guidance is $4.9–5.3B (+64–77% at constant currency) [FACT, Q1-26 call].

The business quality is high: ~81% gross margins, recurring chronic-dosing revenue, and a demonstrated ~46% incremental operating margin that converts top-line growth into profit at a rapid clip now that the fixed commercial and R&D base is covered. The moat is real but should be named precisely: it is an intangibles/IP advantage (the RNAi + GalNAc-conjugate delivery patent estate and two decades of chemistry/manufacturing know-how) reinforced by a first-mover scale lead in TTR. It is not a self-evidently repeatable “platform that mints blockbusters” — every future drug still carries independent clinical, regulatory, competitive and reimbursement risk, and today ~70%+ of revenue rests on one protein target.

The central tension for the investor is that the fundamentals inflected up while the stock de-rated down. ALNY fell ~43% from its $491 October-2025 high to $278, compressing EV/sales to ~13.6x trailing and ~8.6x forward — the cheapest sales multiple in the company’s public history (its lowest-ever sales multiple measured against its own multi-year range) — even as it turned profitable. Three legitimate concerns explain the discount: (1) earnings quality — FY25 stock-based compensation of $348M actually exceeded GAAP net income of $314M, so the maiden profit is thin once SBC is charged as a true economic cost; (2) concentration and competition — the growth indication (ATTR-CM) is precisely the move out of cosy ultra-orphan economics into a large cardiology market where Pfizer’s tafamidis, BridgeBio’s fast-rising acoramidis (Attruby), and Ionis/AstraZeneca’s eplontersen (Wainua) all compete; and (3) policy — the IRA’s Medicare price-negotiation clock and the fragility of AMVUTTRA’s orphan-drug exemption visibly constrain strategy. Against these sit a deep, optionality-rich pipeline (next-gen TTR silencer nucresiran for ~twice-yearly dosing by 2030; zilebesiran in hypertension; programs in obesity, Huntington’s, Alzheimer’s, bleeding disorders), a net-cash balance sheet, and persistent strategic-takeover optionality. This memo argues the franchise is genuinely good, the price is no longer demanding, and the debate is now about durability and concentration, not viability.

2. Business Overview

What Alnylam does. Alnylam discovers, develops and commercializes RNA-interference (RNAi) therapeutics — small interfering RNAs (siRNAs) that silence a disease-causing gene’s messenger RNA before the pathogenic protein is ever made. This is mechanistically distinct from antibodies or small molecules, which act on a protein after it exists. The company’s foundational commercial innovation is the GalNAc (N-acetylgalactosamine) conjugate, a sugar tag that delivers siRNA selectively to liver hepatocytes and enables potent, durable, subcutaneous, infrequent dosing (quarterly, and with next-generation chemistry, potentially twice-yearly). For tissues beyond the liver, Alnylam has extended the toolkit — a C16 lipophilic conjugate for CNS/ocular delivery, and its first product (ONPATTRO) used a lipid nanoparticle [FACT, FY25 10-K]. The siRNA mechanism is catalytic (it co-opts the cell’s RISC machinery), which is the biological basis for the durability advantage versus competing modalities.

The commercial portfolio. Six Alnylam-invented medicines are on the market, collectively generating several billion dollars annually [FACT, Q1-26 call]:

• TTR franchise — the crown jewel (~67% of FY25 revenue). AMVUTTRA (vutrisiran) — the quarterly subQ silencer — approved for ATTR polyneuropathy and, critically, ATTR cardiomyopathy (FDA, 20-Mar-2025, on the HELIOS-B outcomes trial). FY25 AMVUTTRA revenue ~$2,313.8M (+138%); Q4-25 ~$827M; Q1-26 helped drive TTR (AMVUTTRA + ONPATTRO) to $910M in the quarter. ONPATTRO (patisiran) — the original LNP-based TTR drug — is in deliberate, managed decline (~$172.8M, −32%) as the franchise migrates patients to the superior AMVUTTRA profile.
• Rare-disease annuities (~$500M, ~13%). GIVLAARI (givosiran) for acute hepatic porphyria (~$308.5M, +21%) and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (~$191.4M, +15%). Small, ultra-orphan, durable, high-margin.
• Partnered / royalty (collaboration $553M + royalty $174M in FY25). Leqvio (inclisiran) for LDL-cholesterol lowering — discovered by Alnylam, licensed to and commercialized by Novartis; Alnylam earns a fast-growing royalty (royalty revenue +90% in FY25, +85% in Q1-26). Qfitlia (fitusiran) for hemophilia, with Sanofi. Zilebesiran for hypertension, partnered with Roche (Phase 2/3). A deep Regeneron collaboration in CNS/ocular/hepatic targets (e.g., cemdisiran in myasthenia gravis; mivelsiran/ALN-APP in Alzheimer’s and cerebral amyloid angiopathy).

Revenue model and quality. ~80% of revenue is net product revenue — chronic, lifelong, high-persistence dosing of severe genetic disease, which is high-quality recurring revenue. Royalties (largely Leqvio) are recurring and growing. Collaboration revenue (~15%) is the lumpier, lower-quality slice (milestones; e.g., Q1-26 collaboration fell 17% YoY purely because a $30M Vir milestone fell in the prior-year period). The mix is improving as product revenue scales [INTERPRETATION].

Strategy — “Alnylam 2030.” Management has reframed its long-range plan around three pillars: (1) establish global TTR leadership by revenue while building a durable franchise; (2) grow through sustainable innovation — committing to “at least 2 new transformative medicines beyond TTR with blockbuster potential,” RNAi delivery to ≥10 tissue types, and >40 clinical programs by end-2030; and (3) scale with discipline for durable, profitable growth, investing ~30% of revenue in non-GAAP R&D through the period [FACT, Q1-26 call]. The strategy is explicit that TTR carries today’s P&L and the rest of the pipeline is the next decade’s bet.

Verdict: A high-quality, high-gross-margin, recurring-revenue specialty-pharma franchise that has just reached self-sustaining profitability — with a structural caveat that one protein target (TTR) is, for now, essentially the entire investable cash flow.

3. Industry Dynamics

Structure. Alnylam sits at the intersection of two industry profit pools: rare/orphan genetic medicine (its historical home) and, newly, large-market cardiology (where ATTR-CM lives). Orphan biopharma is structurally one of the better neighborhoods in healthcare: lifelong dosing of severe, genetically-defined disease yields durable demand; premium pricing meets limited payer resistance when patient numbers are tiny and alternatives are scarce; orphan designations confer extended regulatory and pricing exclusivity; and gross margins routinely exceed 80%. Alnylam’s legacy products (porphyria, PH1, TTR-polyneuropathy) embody these economics.

The modality landscape. Genetic medicine splits into competing modalities, and understanding ALNY requires placing RNAi among them [FACT/INTERPRETATION]:

• RNAi / siRNA — Alnylam is the clear leader; also Arrowhead and (post-acquisition) Novo/Dicerna.
• Antisense oligonucleotides (ASO) — Ionis is the pure-play pioneer; its GalNAc-ASO eplontersen (Wainua, partnered with AstraZeneca) is the direct TTR-lowering competitor.
• Gene therapy (one-time AAV) — a different value proposition (durability vs. manufacturing/safety/again-dosing risk).
• In-vivo gene editing / CRISPR — Intellia’s nex-z (NTLA-2001) is a one-and-done TTR editor in Phase 3 and the genuine long-term disruptor to chronic TTR silencing.
• Small-molecule TTR stabilizers — Pfizer’s tafamidis and BridgeBio’s acoramidis, the incumbent and fast-follower oral agents in ATTR-CM.

RNAi vs. ASO: both lower TTR, but siRNA’s catalytic mechanism supports longer durability and less-frequent dosing (AMVUTTRA quarterly vs. Wainua monthly) — a real, if incremental, convenience edge [INTERPRETATION; corroborated by label and trade press].

Reimbursement & the orphan-to-cardiology migration (the key structural risk). ATTR-CM is not an ultra-orphan market — it is a large heart-failure indication where Pfizer’s Vyndaqel/Vyndamax franchise already exceeds ~$5B globally, where oral stabilizers are cheaper and more convenient, and where payers scrutinize a multi-billion-dollar category. AMVUTTRA’s defense is outcomes data (HELIOS-B: significant reduction in all-cause mortality + CV events, plus an amyloid-regression signal and renal-preservation data presented at ACC/AHA) and quarterly dosing that drives >90% real-world adherence — a sharp contrast to the lower persistence typical of daily oral agents [FACT, ACC 2026 real-world data]. The migration is voluntary and value-accretive (a far larger pie), but it trades the protected economics of ultra-orphan for the competitive economics of cardiology.

IRA / policy (material, structural). The Inflation Reduction Act’s Medicare drug-price-negotiation clock is the single biggest policy overhang. AMVUTTRA’s orphan-drug exemption currently shields it, but adding non-orphan indications can accelerate negotiation eligibility; industry analysis frames the difference as roughly ~14 vs. ~9 years of price-protected exclusivity — and losing ~5 years removes a disproportionate share of lifetime revenue/profit [INTERPRETATION, RApport/RACap]. Tellingly, Alnylam is visibly sequencing label expansions to preserve the exemption — the IRA is actively shaping its pipeline strategy. This is an industry-wide orphan-biopharma headwind, not an ALNY-specific flaw.

Barriers to entry. Real and modality-deep: (1) the GalNAc-delivery + chemistry patent estate, with claims covering GalNAc-conjugated chemically-modified RNAi broadly (independent of sequence/target) and repeatedly expanded by new USPTO allowances; (2) two decades of manufacturing and clinical know-how; and (3) a cross-licensing web (Ionis pays Alnylam for RNAi; Alnylam licenses Ionis ASO motifs; Dicerna cross-license) that turns rivals into partial licensees. AMVUTTRA’s exclusivity stack runs to roughly 2030 (data) / 2032 (orphan/market) in the EU, with a US composition-of-matter + orphan stack behind it [FACT, 10-K].

Verdict: Structurally attractive industry, with a sharpening edge. Orphan genetic medicine is a genuinely good business; RNAi sits behind real modality barriers. The open question is whether ATTR-CM’s larger-market economics — competition, payer scrutiny, IRA exposure — dilute the orphan moat the company was built on. Good neighborhood; the company is voluntarily moving toward its more contested end.

4. Competitive Position

The moat, named precisely. In Greenwald’s taxonomy, Alnylam’s durable advantage is intangibles/IP (the RNAi + GalNAc patent and delivery estate) reinforced by a first-mover/scale lead in TTR. This is more than most biotechs possess: the platform genuinely lowers the technical cost and risk of each new liver-targeted siRNA, and is being extended to new tissues. But it is not a moat that guarantees serial commercial winners — it reduces technical risk on the next program; it does not reduce market risk. Each future drug remains its own clinical, regulatory, competitive and reimbursement bet, and the P&L today is ~70%+ one protein.

Greenwald tests.

• Market-share stability. In the legacy ultra-orphan indications (TTR-PN, porphyria, PH1) Alnylam holds dominant, stable share — moat-supportive. In TTR-PN specifically, even after eplontersen’s entry, AMVUTTRA holds >75% of new-patient starts while the category keeps growing [FACT, Q1-26 call]. In ATTR-CM, the market is new and contested: Pfizer (incumbent, $5B+ but facing tafamidis patent/generic erosion), BridgeBio’s Attruby (acoramidis) — a potent newer oral stabilizer taking deep first-line penetration — and AMVUTTRA, which as the third entrant has already reached >35% first-line share within ~9 months of launch. Share is being fought for in CM (fails the stable-share test for the growth indication) while comfortably defended in the legacy ones.
• ROIC. FY2025 is the first profitable year, so multi-year ROIC is not meaningful (deeply negative 2020–24). ROIC.ai’s FY25 return_on_inv_capital of ~28% conflicts with its return_on_capital of ~−9.8% — an artifact of a single transitional profitable year over a large accumulated deficit and a convertible-heavy capital structure. Treat ~28% as an un-validated point estimate, not a through-cycle return. More importantly, the economic invested capital is far larger than the balance sheet shows: ~$6.7B of cumulative R&D was expensed, not capitalized, so true returns on cumulative capital deployed are materially lower than any GAAP-balance-sheet ROIC suggests [INTERPRETATION — the key caveat on the “high-ROIC” framing]. What is unambiguous is the operating leverage: 81.6% gross margin and ~46% incremental operating margin mean economics improve sharply with scale.

The ATTR-CM competitive matrix (FACT).

• AMVUTTRA (vutrisiran, Alnylam): RNAi silencer; subQ q3 months; HELIOS-B mortality/CV-event reduction + amyloid-regression signal; the only approved silencer in CM; >90% adherence. Edge: mechanism (lowers the amyloidogenic protein, not just stabilizes it), outcomes, low pill burden. Disadvantage: injection vs. a pill, higher price than stabilizers.
• Vyndaqel/Vyndamax (tafamidis, Pfizer): incumbent oral stabilizer, multibillion installed base — but a Pfizer patent settlement now frames a defined generic timeline. Management argues (credibly) that its growth is not tethered to tafamidis genericization, because nearly half of stabilizer patients keep progressing and need an orthogonal mechanism.
• Attruby/Beyonttra (acoramidis, BridgeBio): the most dynamic share-gainer of 2025 — a newer, near-complete-stabilization oral. The single biggest competitive threat to AMVUTTRA’s first-line ambitions.
• Wainua (eplontersen, Ionis/AstraZeneca): GalNAc-ASO silencer; approved in PN; Phase 3 CARDIO-TTRansform CM readout due later 2026, including an upsized silencer-on-stabilizer combination arm — the direct silencer threat. Notably, Wainua’s PN revenue fell ~35% Q/Q in early 2026, suggesting AMVUTTRA is out-competing it in the existing indication [FACT, Q1-26 call].

Is silencing advantaged vs. stabilizing? Mechanistically yes — removing the substrate should beat stabilizing it, and HELIOS-B’s regression signal supports the thesis. AMVUTTRA’s own label already captures efficacy on or off tafamidis (i.e., as monotherapy and in combination), which management leverages commercially. But the market reality is that oral stabilizers’ convenience and lower price are winning meaningful share now, and the silencer category itself becomes competitive once Wainua-CM arrives. Alnylam’s longer-term answer is nucresiran (ALN-TTRsc04) — Phase 1 showed >95% TTR knockdown sustained at six months from a single dose, supporting twice-yearly (potentially annual) dosing; the Phase 3 TRITON-CM trial, just upsized from 1,250 to ~1,750 patients on faster-than-expected enrollment, targets approval by ~2030. If once- or twice-yearly dosing materializes, it re-widens the convenience gap versus pills — but that is a 2028–2030 event, leaving a multi-year window of price/convenience competition.

Platform vs. product-by-product (the pressure-test). Alnylam’s platform is real infrastructure and has been executed once, convincingly, in TTR — a self-built ~$3B+ franchise and a first GAAP profit. Versus Ionis (the other RNA-platform pure-play, which has many partnered shots-on-goal but a thinner record of self-commercialized blockbusters), Alnylam is clearly ahead commercially. But the bull case requires the platform to translate again into a large-market winner — and the next big test (zilebesiran in hypertension) is a far harder, more crowded market than ultra-orphan TTR. Verdict: a genuine, narrow, durable moat protecting the existing TTR franchise (intangibles/IP + first-mover scale), plus real-but-unproven optionality beyond it. This is a strong specialty-pharma franchise carrying a platform call-option — not a self-evidently repeatable compounding machine.

5. Growth History and Forward Opportunities

The historical record. Revenue compounded from $493M (2020) → $844M (2021) → $1,037M (2022) → $1,828M (2023) → $2,248M (2024) → $3,714M (2025) — a ~5-year CAGR near 50%, with gross margin holding in a remarkably stable 81–86% band throughout [FACT]. The growth is overwhelmingly organic (no meaningful M&A) and volume/demand-driven rather than price-driven — a high-quality profile. The 2024→2025 acceleration (+65%) is almost entirely the AMVUTTRA ATTR-CM launch following the March-2025 approval.

Quality of growth. High. It is (a) organic, (b) demand-led (management was explicit on the Q1-26 call that sequential US growth was “primarily demand-driven,” with inventory benefit offset by gross-to-net), © recurring (chronic dosing, >90% adherence/persistence over multi-year real-world follow-up), and (d) increasingly profitable (the incremental operating margin of ~46% means growth now self-funds). The one quality caveat is geographic/segment concentration: TTR is the dominant driver, so franchise growth ≈ TTR growth.

Forward opportunities, in rough order of certainty and size.

1. AMVUTTRA ATTR-CM penetration (near-term, large, high-confidence). ATTR-CM is ~200,000 US patients, >80% untreated; the category grew ~77% since competitive launches. FY26 TTR guidance of $4.4–4.7B implies continued rapid penetration. Management’s three launch KPIs — prescriber-base expansion (>1,200 new US prescribers since launch), category growth (AI-enabled diagnosis partnerships with Viz.ai and the American Heart Association), and adherence/persistence — are the right ones to track.
2. Ex-US ATTR-CM rollout (near-term, moderate). CM launches underway in Japan (tracking to “leading analogs”), and across Europe (Austria, UK, Switzerland, Italy) with favorable HTA outcomes. A near-term drag is that launching CM ex-US triggers a price adjustment on the existing PN base (Germany was the largest Q1-26 hit) — a deliberate mix-shift trade of a smaller high-price segment for a far larger population.
3. Nucresiran (next-gen TTR, ~2030). Twice-yearly dosing would defend and extend TTR leadership into the next decade and refresh the exclusivity/IP runway.
4. Beyond-TTR pipeline (the optionality, 2027–2030+). Zilebesiran (hypertension; ZENITH CV-outcomes trial) — the next large-market test. ALN-6400 (bleeding disorders). ALN-2232 (first adipose-directed RNAi, obesity/weight management — a Phase 1 start in a vast market). ALN-HTT02 (Huntington’s). Mivelsiran (Alzheimer’s/CAA, with Regeneron). Cemdisiran (myasthenia gravis, Regeneron). Management’s “Alnylam 2030” commitment is ≥2 new blockbusters beyond TTR.
5. Royalty growth (steady). Leqvio royalties compounding (+85–90%) as Novartis scales inclisiran.

Verdict: high-quality growth — organic, demand-led, recurring, and now profitable — with a deep optionality stack on top. The honest qualifier: the high-confidence growth is TTR; everything beyond TTR is genuine but unproven, and the FY26 guide requires meaningful back-half sequential acceleration to hit.

6. Financial Quality

The inflection, in numbers. FY2025 vs. FY2024: revenue $3,714M vs. $2,248M (+65%); gross profit $3,032M (81.6% margin) vs. $1,925M; operating income +$501.6M vs. −$176.9M; net income +$313.7M vs. −$278.2M; diluted EPS +$2.33 vs. −$2.18; EBITDA $557M vs. −$120M; operating cash flow +$524M vs. −$8M; free cash flow ~$465M [FACT]. The operating swing of ~$679M on $1,466M of incremental revenue is a ~46% incremental operating margin — the single most important number in the financials, because it quantifies how much of future TTR growth drops to profit over a now-largely-fixed cost base.

Operating-expense structure. FY25 R&D $1,320M (~35.5% of revenue) and SG&A $1,211M (~32.6%). R&D is rising in absolute dollars (three Phase 3 programs — ZENITH/zilebesiran, TRITON-CM and TRITON-PN/nucresiran — plus early pipeline) but falling as a share of revenue: the textbook signature of a platform reaching operating leverage. Management guides to ~30% of revenue in non-GAAP R&D through 2030. SG&A at ~33% reflects the global CM launch build and should decelerate as a percentage as AMVUTTRA scales [INTERPRETATION] — the line to watch for commercial discipline.

The quality-of-earnings caveat (important). The maiden GAAP profit is real on a cash basis (OCF $524M) but thin once stock-based compensation is charged as the true economic cost it is: FY25 SBC of $348M exceeded GAAP net income of $314M. On an owner-earnings basis (net income burdened fully by SBC), FY25 is roughly breakeven-to-slightly-positive. This does not negate the inflection — the trajectory and the incremental margin are what matter, and both are excellent — but it means an investor paying ~66x trailing GAAP earnings is paying for the forward leverage, not for a clean current profit. A second, subtler QoE point from the Q1-26 call: gross margin will step DOWN over the course of 2026 (80% in Q1 vs. 85% a year earlier) because the royalty Alnylam pays Sanofi on AMVUTTRA resets and rises each calendar year as sales grow — so reported gross margin mechanically erodes through the year even as the business strengthens [FACT, Q1-26 call]. Model gross margin in the low-80s/high-70s, not mid-80s.

Balance sheet — fortress-adjacent and deleveraging fast. YE25 cash + marketable securities of $2.91B (Q1-26: $3.0B) against total debt of ~$1,278M (convertible senior notes due 2027/2028 + ~$271M capital leases), for net cash of ~$649M — a flip from net debt of $58M at YE24 [FACT]. Net debt/EBITDA −1.2x; EBITDA/interest ~2.2x (gross interest expense of $253M is the lingering cost of the leverage-heavy build, now comfortably covered and falling as a burden). Current ratio 2.8x. Reported GAAP book equity is small (~$789M; tangible book ~$6/share) — an artifact of two decades of expensed R&D, which is why P/B (~36x) is essentially meaningless here and should be ignored in favor of P/S and earnings power [INTERPRETATION; on its own multi-year range P/B sits near the high end but P/S near the low — read P/S].

Cash conversion. FY25 OCF of $524M exceeded net income (cash-flow-to-NI 1.67x), helped by SBC add-back and partly offset by a $445M working-capital build (receivables +$360M as the franchise scaled). Capex is light (~$59M), consistent with an asset-light, manufacturing-outsourced specialty-pharma model. Free cash flow ~$465M and inflecting.

Verdict: economics improve dramatically with scale — yes, emphatically. Gross margin ~81%, ~46% incremental operating margin, net cash and deleveraging, light capex, and inflecting FCF. The one honest asterisk: charge SBC as a real cost and the current profit is thin; the case rests on the forward leverage, which the numbers strongly support.

7. Capital Allocation

The 20-year question, now answered. Alnylam spent its way to a ~$6.7B accumulated deficit building the RNAi platform. For most of its life that looked like value destruction; FY2025 is the first hard evidence it was value creation — the accumulated deficit actually shrank (from $7.29B at YE24 to $6.70B at YE25) as net income began flowing back into retained earnings. R&D intensity is falling as a share of revenue even as absolute R&D rises — the right shape. Verdict on the core question: above-average capital allocation, now vindicated by the numbers [INTERPRETATION, high conviction].

The funding strategy — creative and minimally dilutive. The keystone was the April-2020 Blackstone ~$2B strategic financing: $1B to monetize 50% of the inclisiran (Leqvio) royalty stream (a non-recourse royalty sale, not equity), up to $750M in senior secured term loans, $150M in cardiovascular R&D funding, and a $100M equity purchase — explicitly to reach “a self-sustainable financial profile without need for future equity financing” [FACT, Blackstone/Alnylam, 13-Apr-2020]. That is exactly what played out. Selling half the Leqvio royalty looks expensive in hindsight given Leqvio’s ramp, but in the depths of 2020 it was a shrewd way to pull forward non-dilutive cash against an asset Alnylam doesn’t even commercialize itself. Combined with the out-licensing/partner model (Novartis, Sanofi, Roche, Regeneron carry development cost and risk in exchange for economics), this kept equity dilution to ~2.6%/year (116.4M shares at YE20 → 132.4M at YE25) through a deep cash-burn — genuinely impressive discipline for a clinical-stage-to-commercial biotech.

M&A — organic by design. Alnylam is not an acquirer; growth is programs, not bolt-ons. No goodwill, no integration risk, no overpayment-for-pipeline destruction. Capital flows the other way (out-licensing). Alnylam is itself a perennial strategic-stake/takeover-rumor name — Regeneron (deep multi-program partner), Roche, Novartis and Sanofi all carry economic exposure — which is live optionality, not a base case. The 2026 proxy’s top holders are passive (Fidelity ~12.4%, Vanguard ~9.8%, BlackRock); no 5%+ strategic pharma stake is disclosed [FACT, 2026 DEF 14A].

SBC, buybacks, dividends. SBC of $348M (~9.4% of revenue) is moderate-to-high for the sector and, as noted, exceeded FY25 net income — the central QoE flag. No dividend, no buyback — correct and appropriate: a franchise compounding revenue ~50%+ with a maturing pipeline should reinvest every dollar; returning capital here would be an error.

Compensation & alignment (2026 DEF 14A) — competent, with one structural gap. The annual cash bonus pays on a corporate-performance modifier across “Culture / Early Pipeline & Development / Marketed Products & Financial Performance” (the last including net-product-revenue and investment-plan targets); the board approved a 200% modifier for 2025 (the cap) on +65% revenue and maiden profitability — defensible on results. CEO Yvonne Greenstreet’s FY25 total comp was $14.87M, ~93% at-risk; long-term equity is 50% PSUs / 25% RSUs / 25% options, with PSUs vesting only on clinical/regulatory/financial events. A special March-2026 PSU vests only on demanding 30-day-average stock-price hurdles of $600 / $700 / $800 over 46 months — genuinely stretched and shareholder-aligned on direction. The gap: there is no return-on-capital / ROIC / ROE governor anywhere in the plan — management is paid to grow and advance, not to earn above the cost of the capital consumed. For a company that just spent $6.7B, that is a real (if cohort-common — cf. PCG, PPL, CBRE) weakness.

Insider behavior — the soft spot. Directors + officers as a group own <1% of the company; founding CEO John Maraganore departed years ago and there is no anchoring founder block. The trailing Form 4 record (237 filings in five years) is all routine vesting / option-exercise / 10b5-1 disposition — zero discretionary open-market purchases (code P). In a year the thesis arguably de-risked and the stock fell 43%, no insider bought with their own cash. This neither corroborates nor contradicts the fundamentals, but it offers no insider vote of confidence — neutral-to-mildly-negative on conviction.

Verdict: above-average capital allocation (vindicated platform spend, creative low-dilution funding, organic discipline, correct no-return-of-capital stance), wrapped in a softer governance shell (no capital-efficiency incentive metric, <1% insider ownership, zero insider buying).

8. Changes and Headwinds — Last Two Years

Strategic / commercial.

• The defining event: AMVUTTRA ATTR-CM approval (20-Mar-2025) and launch — converting Alnylam from a perennial burner into a profitable, fast-scaling commercial company. Three consecutive quarters of GAAP profitability through Q1-26; first-ever $1B+ product-revenue quarter (Q1-26).
• Alnylam 2030 plan unveiled (≥2 blockbusters beyond TTR, ≥10 tissue types, >40 clinical programs, ~30% revenue in non-GAAP R&D).
• Pipeline progression: nucresiran TRITON-CM upsized (1,250→~1,750 patients) on fast enrollment; new Phase 1 starts in obesity (ALN-2232) and ongoing programs in Huntington’s, Alzheimer’s/CAA, bleeding disorders, hypertension (zilebesiran ZENITH).
• New commercial collaborations to drive TTR diagnosis (Viz.ai, American Heart Association AI-diagnosis; GENESIS Pharma expansion into Nordic markets, Jun-2026; Medison into LATAM/APAC).

Competitive / regulatory headwinds.

• BridgeBio’s Attruby (acoramidis) “crushed expectations” and is the most dynamic first-line share-gainer in ATTR-CM — the principal competitive threat.
• Ionis/AstraZeneca’s Wainua (eplontersen) CM readout (CARDIO-TTRansform, including an upsized silencer-on-stabilizer combination arm) is due later 2026 — a direct silencer challenge; though Wainua’s PN sales fell ~35% Q/Q in early 2026, a sign AMVUTTRA is winning the existing indication.
• Pfizer tafamidis generic settlement defines a generic timeline; management argues limited impact (growth not tethered to stabilizer genericization).
• IRA orphan-exemption fragility continues to shape label-expansion sequencing.
• Ex-US pricing resets (Germany the largest in Q1-26) as CM launches trigger PN-base price adjustments — a deliberate mix-shift drag.
• The Q4-2025 print (12-Feb-2026) candidly flagged Q1 gross-to-net and reauthorization headwinds; the stock broke from ~$397 to ~$308 and has since drifted to a 52-week low.

Verdict: net thesis-strengthening on fundamentals (the inflection is the dominant fact), but the competitive and policy environment is genuinely intensifying — the headwinds explain the de-rate even as the business improved.

9. Risk Analysis

Net read: the dominant risks are concentration + intensifying competition in the one market that matters, layered on a thin-ex-SBC current profit and a structural IRA overhang. None is existential; together they are sufficient to justify a discount and to keep conviction at medium rather than high.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At $278, market cap ~$52B and EV ~$50B (net cash ~$649M). On trailing figures: ~66x GAAP P/E, ~13.6x EV/TTM-sales, ~91x EV/TTM-EBITDA. On forward figures (FY26 product-revenue guide $4.9–5.3B; total revenue plausibly ~$5.6–6.0B with collaboration/royalty): ~8.6x forward EV/product-sales. The critical own-history context: EV/sales has compressed from ~22–30x in 2020–2022 and ~12–13x in 2023–2024 to a forward ~8.6x — the cheapest sales multiple in the company’s public history — the lowest measured against its own multi-year range. P/B (~36x) is a meaningless artifact of expensed-R&D book equity — ignore it. P/E (~66x trailing) is distorted by the just-crossed-breakeven denominator and by SBC; on FY26E EPS (consensus ~$8–9, given the Q1-26 $1.99 print and EPS beat) the forward P/E is closer to ~30–35x, and on FY27E it compresses further as leverage compounds.

Sector comp frame. ALNY’s factor-similar / large-cap-profitable-biotech peers (per FactorsToday related-stocks and the modality set) include Regeneron, Vertex, Incyte, United Therapeutics, Genmab, Ionis (RNA twin), BridgeBio (direct ATTR-CM competitor), and the IBB/FBT biotech indices. Mature profitable biotech (VRTX, REGN) trades ~5–6x sales / ~15–25x earnings but grows mid-single to low-double digits; ALNY is growing 65%+ with ~46% incremental margins. On a growth-adjusted basis, ~8.6x forward sales for that growth-and-margin profile is not demanding — the de-rate has removed the premium, not created a deep-value bargain.

Embedded-expectations read. What is the market underwriting at $278?

• Correctly priced: TTR leadership and continued strong AMVUTTRA CM penetration — the FY26 guide is largely in the number. The market is not assuming a launch failure (the stock would be far lower).
• Skeptically priced / discounted: durability of TTR economics against intensifying competition and IRA, and the quality of the profit (SBC). The de-rate says the market doubts the moat’s durability and the margin’s cleanliness, not the current trajectory.
• Close to free: essentially the entire beyond-TTR pipeline (zilebesiran in a multi-hundred-billion hypertension market, obesity, Huntington’s, Alzheimer’s, bleeding disorders) and nucresiran’s next-decade TTR extension. A reverse-DCF that solves for ~$278 on TTR alone leaves the “2 blockbusters beyond TTR” ambition as an unpriced call option. That asymmetry is the core of the valuation case.

Scenario sketch (illustrative, not a target).

• Bear: ATTR-CM becomes a price-competitive slugfest, Attruby/Wainua cap AMVUTTRA share, IRA bites, beyond-TTR pipeline disappoints. Revenue plateaus ~$6–7B, margins capped by competition; the stock re-rates to ~5–6x sales → meaningfully lower.
• Base: AMVUTTRA reaches the guided ramp and TTR leadership; rare-disease and royalties compound; one beyond-TTR program (zilebesiran or obesity) advances. Revenue to ~$7–9B by ~2028 with expanding margins; ~9–11x forward sales holds → fair value materially above spot.
• Bull: AMVUTTRA dominates a growing CM category, nucresiran extends the franchise, and zilebesiran/obesity validate the platform’s repeatability. The market re-rates the whole pipeline → well above current levels and a strategic bid becomes plausible.

No price target, no recommendation — per firm policy. The embedded-expectations conclusion: at the cheapest sales multiple in its history, the market is paying for TTR and pricing the rest of the platform near zero, while discounting competition/IRA/SBC. Whether that is too pessimistic is the entire debate.

11. Variant Perception

Consensus belief. ALNY is a high-quality RNAi leader that just inflected to profitability, but the easy money was made into the October-2025 high; competition (Attruby, Wainua), IRA, and a high multiple argue for caution — hence the de-rate. Sell-side is broadly positive on the franchise but the stock has acted poorly.

The strongest bull case. You are buying a demonstrated platform — not a hope — at its cheapest-ever sales multiple, right as 46% incremental margins turn 65%+ revenue growth into compounding profit, with the entire beyond-TTR pipeline (a multi-hundred-billion hypertension TAM, obesity, CNS, bleeding) thrown in close to free and a strategic-acquisition floor under the stock. The market is extrapolating a Q1 phasing wobble and competitive noise into a durability problem that the >75% PN share and >35% first-line CM share (as the third entrant) directly contradict.

The strongest bear case. This is a one-protein company (~70%+ TTR) charging into a competitive cardiology market it doesn’t own, where a better-tolerated oral (Attruby) is taking first-line share and a silencer rival (Wainua) reads out a combination trial later in 2026; the “profit” is an SBC mirage ($348M SBC > $314M NI); the IRA structurally caps the franchise’s lifetime value; and “2 blockbusters beyond TTR” is an unproven 2028–2030 promise from a company whose only commercial success to date is TTR. At ~66x trailing earnings, any stumble re-rates it hard — and insiders, who know most, are selling, not buying.

The 3–5 assumptions that matter most:

1. AMVUTTRA sustains first-line CM share against Attruby and (post-readout) Wainua. Falsified by: sequential first-line share erosion or a guide cut.
2. The FY26 $4.4–4.7B TTR ramp materializes in the back half. Falsified by: a Q2/Q3 miss or reiterated-flat guidance into year-end.
3. The orphan/IRA exclusivity runway holds long enough to harvest the franchise. Falsified by: an adverse IRA-negotiation selection or a label move that forfeits the exemption.
4. At least one beyond-TTR program validates the platform’s repeatability (zilebesiran ZENITH, or obesity/ALN-2232, or HD/AD). Falsified by: successive Phase 2/3 failures.
5. SBC normalizes as a share of revenue so owner-earnings converge toward GAAP. Falsified by: SBC staying ≥9% of a much larger revenue base.

Factor-positioning read (from the tape). ALNY is not a crowded momentum trade — it is the opposite: below all major EMAs, −29% over six months, market beta ~0.80, returns ~75% idiosyncratic (R² ~25%), and sitting at its 52-week low. Risk-adjusted track record is poor short-term (negative 1-year/6-month Sharpe) but solid long-term (positive 3/5/10-year). This is an abandoned / de-rated quality name, which is exactly where consensus is most likely offsides if the fundamentals hold — the market is treating an operating-leverage inflection like a busted growth story. The variant view is that the price action reflects positioning and multiple-compression, not a deterioration in the business that the KPIs simply do not show.

12. Fact vs. Interpretation Table

13. Open Questions

1. Where does AMVUTTRA’s first-line CM share settle once Attruby matures and Wainua’s CARDIO-TTRansform reads out — and does the silencer-on-stabilizer combination paradigm help or commoditize the silencer class?
2. How much of the FY26 guide is demand vs. price/inventory phasing, and does the back-half ramp arrive on schedule?
3. What is the true normalized gross margin once the Sanofi AMVUTTRA royalty fully steps up and ex-US CM price resets annualize — high-70s or low-80s?
4. Does the IRA force a strategic choice between label breadth and exclusivity, and how does management sequence it?
5. Which, if any, beyond-TTR program (zilebesiran, obesity/ALN-2232, HD, AD) first validates platform repeatability — and on what timeline?
6. Does SBC normalize toward a smaller share of a larger revenue base, converging owner-earnings to GAAP?
7. Is a strategic bid plausible, and at what premium, given the scarcity value of the platform?
8. What is the long-tail threat from in-vivo CRISPR (Intellia nex-z) to chronic TTR silencing economics late-decade?

14. What Must Be True

Bull case — what must be true:

• AMVUTTRA defends and grows first-line ATTR-CM share through the Attruby/Wainua competitive wave (>30% first-line, >70% PN new starts sustained).
• The FY26 $4.4–4.7B TTR ramp lands, confirming the launch is accelerating, not plateauing.
• Operating leverage continues (incremental margin ~40%+), and SBC falls as a share of a growing revenue base, so owner-earnings converge upward.
• At least one beyond-TTR program advances toward approval, re-rating the unpriced pipeline option.
• Falsification test: a quarter showing sequential first-line CM share loss to Attruby and a TTR guidance cut — that would break the durability thesis and confirm ATTR-CM as a competitive commodity market rather than an Alnylam-led one.

Bear case — what must be true:

• ATTR-CM proves a price-competitive cardiology slugfest; AMVUTTRA’s injection loses first-line ground to oral stabilizers; the category’s value migrates to cheaper agents.
• IRA negotiation/exemption loss caps lifetime franchise value; the orphan economics the company was built on erode in its biggest market.
• The beyond-TTR pipeline disappoints (zilebesiran/obesity/CNS), leaving a single-protein company at a premium multiple.
• Falsification test: two+ consecutive quarters of accelerating TTR revenue with stable/rising first-line share AND a positive beyond-TTR Phase 2/3 readout — that combination would refute the “one-trick, soon-competed” bear and validate the platform.

15. Source Appendix

See Appendix B — Source Appendix below. Primary sources: Alnylam’s FY2025 Form 10-K (filed 2026-02-12), the Q1-2026 earnings call (30-Apr-2026) and press release, the 2026 DEF 14A proxy (filed 2026-04-06), the trailing five-year SEC filing record, public company disclosures and FDA/clinical announcements, public market price history, and named competitive/industry sources (FiercePharma, BioPharma Dive, Pharmaceutical Technology, RApport/RACap). All figures reconciled to filings where material.

The body of this article contains no investment recommendation and no price target. The only positional view is the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent opinion and general information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire — Alnylam Pharmaceuticals (NASDAQ: ALNY)

Supplemental to the main article. Fact/Interpretation/Assumption labels where it matters. As-of 2026-06-21.

General

What thoughtful questions have other investors asked about this company? The Q1-2026 call Q&A (the sharpest available proxy for institutional concerns) clustered almost entirely on ATTR-CM competitive dynamics: (1) first-line vs. second-line AMVUTTRA use and whether physician experience deepens first-line adoption (Ritu Baral/TD Cowen, Ellie Merle/Barclays); (2) the implications of the competitor silencer Wainua’s CARDIO-TTRansform readout and its silencer-on-stabilizer combination arm (Tazeen Ahmad/BofA, Kostas Biliouris/Oppenheimer, Mike Ulz/Morgan Stanley); (3) the Pfizer Vyndamax generic settlement and whether tafamidis genericization changes the landscape (Jessica Fye/JPMorgan); (4) ex-US pricing resets (Germany) and the 2026 trajectory (Salveen Richter/Goldman); and (5) the selling-weeks / inventory / gross-to-net mechanics behind the modest Q4→Q1 sequential US growth (Paul Matteis/Stifel). The throughline: investors are probing the durability and competitiveness of the TTR franchise, not its viability. [FACT, Q1-26 transcript]

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither cyclical — at an early-inflection point. FY25 is the first profitable year ever; earnings are rising structurally off a near-zero base as operating leverage arrives, not cycling. Driven by external environment or internal actions? Internal — a product launch (AMVUTTRA ATTR-CM) on the back of in-house R&D, not a macro cycle. How stable are revenues? High stability — chronic, lifelong dosing with >90% real-world adherence/persistence; ~80% recurring product revenue. Outlook for products/services? Strong near-term (TTR guide +64–77%); the question is durability vs. competition. Market size? ATTR-CM ~200,000 US patients (>80% untreated) — large and growing; plus a multi-hundred-billion beyond-TTR ambition (hypertension, obesity). Growing, global. [FACT/INTERPRETATION]

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More — Alnylam is voluntarily migrating from ultra-orphan into competitive cardiology (Attruby, Wainua, generic tafamidis). How profitable is the business (ROIC, ROE)? Just turned profitable; FY25 op margin 13.5%, gross margin 81.6%; ROIC-type metrics distorted by the transitional year and expensed-R&D capital base (treat the ~28% ROIC.ai figure cautiously — true returns on cumulative R&D are lower). How profitable is the industry / barriers? Orphan biopharma is high-margin with real barriers (the GalNAc/RNAi patent estate, manufacturing know-how, cross-license web). Can the business be easily understood? Moderately — the commercial story (TTR) is simple; the science and the IRA/exclusivity mechanics are complex. Undermined by foreign low-cost labor? No — IP/regulatory-protected biologics-adjacent therapeutics. Do brands matter? Less “brand” than clinical-outcomes data + physician habit + payer access — AMVUTTRA’s HELIOS-B mortality data and >90% adherence are its franchise. Switching costs? For patients on a quarterly silencer with proven adherence, real stickiness; for prescribers, habit + access. [INTERPRETATION]

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes, hugely — two decades of expensed R&D (~$6.7B accumulated deficit) built the platform/IP that the balance sheet does not capitalize; tangible book is only ~$6/share. The economic value (the RNAi estate, the approved franchise) vastly exceeds book. Off-balance-sheet liabilities? The 50% inclisiran/Leqvio royalty sold to Blackstone (2020) is an economic claim on a revenue stream; standard operating leases. How conservative is the accounting? Reasonable; the main QoE flags are (a) SBC ($348M) exceeding net income, and (b) gross margin mechanically declining through the year as the Sanofi AMVUTTRA royalty resets up. How capex-hungry? Light — ~$59M FY25 capex (~1.6% of revenue); asset-light, manufacturing largely outsourced. [FACT]

Capital Allocation & Management

How much FCF, and how is it used? FY25 FCF ~$465M, inflecting; reinvested in the pipeline (3 Phase 3 programs + early R&D) — no dividend, no buyback, correctly. Philosophy? Self-fund the platform via partner economics and non-dilutive royalty/debt structures; minimize equity dilution (~2.6%/yr through the burn). Significant acquisitions? None of size — growth is organic; Alnylam out-licenses rather than acquires. Buying back shares? No. Issuing large amounts to insiders? SBC ~9.4% of revenue (moderate-high); ~2.6%/yr dilution. Compensation policy? CEO Greenstreet ~$14.87M FY25; 200% bonus payout (cap) on +65% revenue; PSUs tied to clinical/regulatory/financial milestones + stretched $600/$700/$800 price hurdles; no return-on-capital governor (the alignment gap). Motivations of management? Growth/pipeline/share-price aligned; <1% group ownership and zero insider open-market buying temper the conviction read. [FACT/INTERPRETATION]

Valuation & Market Data

ADR / MLP / K-1? No — US C-corp, common stock, NASDAQ Global Select; no K-1. Dividend policy? None (appropriate — reinvesting). How profitable? Newly so — 13.5% FY25 op margin, ~46% incremental; thin once SBC charged. Net income diverging from CFO? Yes, favorably — FY25 OCF $524M > NI $314M (cash-flow-to-NI 1.67x), driven by SBC add-back partly offset by a working-capital build (receivables +$360M). [FACT]

Risks & Downside

Factors that would cause the stock to decline? First-line CM share loss to Attruby/Wainua; a TTR guidance miss; adverse IRA/exclusivity outcome; gross-margin disappointment; a beyond-TTR pipeline failure; further multiple compression on any stumble (it trades ~66x trailing earnings). Risk of catastrophic loss? Low — profitable, net cash ~$649M, $3.0B liquidity, ~$5B+ revenue, diversified product base, strategic-bid floor. Chance of total loss? Very low — this is an established, profitable, cash-generative commercial company, not a clinical-stage binary. [INTERPRETATION]

Recent News & Events

Has the business environment changed recently? Yes — the AMVUTTRA ATTR-CM launch (Mar-2025) transformed the company; competition is intensifying (Attruby share gains, Wainua CM readout pending late-2026, tafamidis generic settlement). Significant acquisitions? None; instead, new commercial collaborations (Viz.ai/AHA AI-diagnosis; GENESIS Pharma Nordic expansion, Jun-2026; Medison LATAM/APAC). Change in accounting policies? None material noted. Recent operational changes? New markets (ex-US CM launches in Japan, Austria, UK, Switzerland, Italy); pipeline expansion (nucresiran TRITON-CM upsized to ~1,750 patients; new Phase 1 starts in obesity/ALN-2232; programs in HD, AD/CAA, bleeding disorders, hypertension); “Alnylam 2030” plan unveiled. [FACT, Q1-26 call + news feed]

APPENDIX B — Source Appendix — Alnylam Pharmaceuticals (NASDAQ: ALNY)

As-of 2026-06-21. Primary sources prioritized; third-party data labeled. All accessed 2026-06-21 unless noted.

Primary — SEC filings & company disclosures

• Alnylam FY2025 Form 10-K (filed 2026-02-12, SEC EDGAR) — revenue segmentation, product/pipeline, IP/exclusivity, GalNAc/delivery, debt (convertible notes due 2027/2028), capital leases, accumulated deficit.
• Alnylam Q1-2026 earnings call transcript & release (30-Apr-2026) — Q1 product revenue $1.036B (+121%); TTR $910M (+153%); EPS $1.99 (vs ~$0.91 est); gross margin 80%; non-GAAP R&D $335M / SG&A $283M / op income $339M; FY26 guidance reiterated (product $4.9–5.3B; TTR $4.4–4.7B); rare disease $126M (+15%); royalty $49M (+85%); collaboration $82M (−17%); Sanofi AMVUTTRA royalty reset mechanics; nucresiran TRITON-CM upsize 1,250→~1,750; competitive Q&A (Attruby, Wainua/CARDIO-TTRansform, Pfizer settlement).
• Alnylam Q4/FY2025 results release (2026-02-12) — AMVUTTRA ~$2,313.8M (+138%); ONPATTRO ~$172.8M (−32%); GIVLAARI ~$308.5M (+21%); OXLUMO ~$191.4M (+15%); collaboration ~$553.4M; royalty ~$174.0M.
• Alnylam 2026 DEF 14A proxy (filed 2026-04-06, SEC EDGAR) — CEO Greenstreet FY25 comp $14,867,600; AIP goal categories + 200% modifier; 50/25/25 PSU/RSU/option mix; special PSU $600/$700/$800 price hurdles; director+officer group <1% ownership; Fidelity 12.4% / Vanguard 9.8% / BlackRock holders.
• Trailing five-year SEC filing record (10-K, 10-Q, 8-K, DEF 14A, Form 3/4/5) — insider-transaction pattern: routine vesting/option-exercise/10b5-1 dispositions, no open-market purchases.
• FDA approval, AMVUTTRA for ATTR-CM (20-Mar-2025): investors.alnylam.com press release.
• HELIOS-B pivotal CM outcomes data + ACC/AHA follow-ups (mortality/CV-event reduction; amyloid regression; diastolic-dysfunction analysis): Alnylam IR + ACC 2026 real-world adherence data.
• Nucresiran (ALN-TTRsc04) Phase 1 (>95% TTR knockdown, twice-yearly dosing): Alnylam IR (Nov-2024).
• Blackstone / Alnylam ~$2B strategic financing (13-Apr-2020): blackstone.com press release; Alnylam IR — $1B inclisiran royalty monetization, up to $750M senior secured term loan, $150M CV R&D funding, $100M equity.

Market & quantitative data (public; reconciled to filings)

• Company financial statements (FY2020–FY2025, from SEC filings): FY25 rev $3,713.9M, op income $501.6M, NI $313.7M, EBITDA $557.2M, SBC $348.2M, OCF $524.1M, FCF ~$465M, net cash ~$649M, EV ~$50.5B, EV/TTM-sales 13.6x; valuation multiples vs the company’s own multi-year range (EV/sales compressed from ~22–30x in 2020–22 to a forward ~8.6x — its lowest-ever).
• Public market price history — ATH close $491.22 (20-Oct-2025); five-year low $120.42 (11-May-2022); current $278.09; 21/50/200-day EMAs $292/$301/$337; factor/risk profile (market beta ~0.80, biotech-industry beta ~1.0–1.2; six-month return ~−29%; long-run positive Sharpe, short-run negative); factor-similar peers ILMN, UTHR, INCY, GMAB, REGN, IBB/FBT.

Secondary — industry / competitive (named publishers)

• FiercePharma — “Alnylam turns profitable even as Amvuttra ATTR revenue disappoints in Q4”; “BridgeBio’s Attruby crushes analyst expectations”; “Patent Office grants Alnylam new GalNAc-delivery claims.”
• BioSpace — “BridgeBio Stock Hits 1-Year High as Attruby Rx Numbers Double.”
• Pharmaceutical Technology — Attruby vs Vyndamax / CARDIO-TTRansform 2026; “AstraZeneca and Ionis challenge Alnylam’s share with Wainua approval.”
• BioPharma Dive — Ionis/AstraZeneca Wainua FDA approval.
• RApport (RACap) — “Alnylam is doing what the IRA is telling it to do” (IRA/orphan-exemption strategy).
• Investing.com / Yahoo Finance / Motley Fool — Q1-2026 results coverage (record $1B+ revenue, EPS beat, guidance).
• Journal of Cardiac Failure — TRITON-CM Phase 3 design rationale.

Where third-party aggregated data and a primary filing disagree on a material number, the filing governs. No third-party analyst price target informs this article; no price target appears outside the labeled Claude’s Take.